The UK will offer Eli Lilly’s weight loss drug, tirzepatide, to people with a body mass index of over 35 and at least one related health condition. The National Health Service will prioritize treating around 220,000 individuals with the highest clinical need, despite eligibility for 3.4 million patients in England alone. This decision comes as the country adapts to new ways of addressing obesity amid increasing demand. Tirzepatide, known as Mounjaro in the UK, will be used in conjunction with a specialized diet and increased physical activity to help those with severe obesity-related health issues.
Source link
U.K. to limit Eli Lilly obesity drug to patients with ‘highest’ need
